Search results
Age-Related Macular Degeneration: Putting a Hole in Our World
WebMD· 6 days agoWhen we’re young, we take our macula for granted. At the center of our retina – the deepest layer of the eye that’s chock-full of photoreceptors and that confers color to our world – the macula ...
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 5 hours agoThis is expected to support regulatory filings for tarcocimab outside the United States in wet AMD....
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Motley Fool via Yahoo Finance· 11 hours agoExcluding its COVID-19 antibody, Regeneron's revenue increased by 7%. Eylea treats wet age-related ...
EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Est
Guru Focus· 6 days agoThe company, known for its innovative ophthalmic products, reported a significant increase in revenue, surpassing analyst expectations for the quarter. EyePoint Pharmaceuticals Inc is a pioneer ...
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look
Guru Focus· 6 days agoOn May 9, 2024, Adverum Biotechnologies Inc (ADVM, Financial), a trailblazer in gene therapy for ocular diseases, disclosed its financial outcomes for the first quarter of 2024 through its 8 ...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer...
The Record Gazette· 3 days agoGLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals, including 6-month ...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
Lodi News-Sentinel· 1 day agoKodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to make excellent operational progress with our ...
Best Ads of the Week: Coi Leray kicks it with Foot Locker & Dove decodes mom life with AI
The Drum· 2 days agoThis week, Editora Taverna fought the good fight against gay conversion therapy Brazil, Vivo rallied...
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Rises By 6.2%
ETF DAILY NEWS· 17 hours agoAdverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) was the target of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling ...
Clearside Biomedical stock target cut, maintains Buy rating By Investing.com
Investing.com· 3 days agoOn Monday, Clearside Biomedical (NASDAQ:CLSD) saw its price target adjusted by H.C. Wainwright. The...